Skip to content
RDL Network logo
FRI-086-YI Long-term survival outcomes in patients receiving atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma: an update of the AB-real study — Bernardo Stefanini (2025) | RDL Network